Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus Pharmaceuticals' stock has been impacted by strong Q1 2026 and Q4 2025 earnings reports, advancements in pipeline programs, insider selling, and overall stock price performance. In Q1 2026, net product sales exceeded $145 million, an increase of over 85% year-over-year. The company reported Q4 2025 net product sales of $151.7 million, contributing to total 2025 net product sales of $451.4 million. Tarsus advanced two pipeline programs in 2026: the Phase 2 Calliope study for Lyme disease prevention (TP-05) and the Phase 2 KORE study for ocular rosacea (TP-04). Insiders have sold approximately $7.9 million worth of stock in the past three months. As of May 1, 2026, the share price was $63.62, a 32.54% increase over the past year.

Demand for Tarsus Pharmaceuticals' products, especially XDEMVY, is seasonal. The first quarter is typically affected by deductible resets, higher out-of-pocket costs, and winter weather, which can reduce new patient visits. Demand is expected to improve in the second quarter, with the fourth quarter generally being the strongest.

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutics, primarily for eye care and infectious disease prevention. Their major product is XDEMVY, an FDA-approved treatment for Demodex blepharitis. The company is also developing TP-04 for ocular rosacea and TP-05 for Lyme disease prevention and community malaria reduction, both in Phase 2 clinical trials.

Tarsus Pharmaceuticals is headquartered in Irvine, California, with the United States as the primary market for XDEMVY. They are also seeking approval for TP-03 (XDEMVY) in Europe, with an estimated timeline for 2027.

Tarsus Pharmaceuticals has maintained a positive brand reputation over the past year due to the successful launch and performance of XDEMVY. The product is considered a successful launch in eye care, improving Demodex blepharitis diagnosis and treatment. The company's direct-to-consumer campaigns have shown strong returns, and they have maintained engagement at key conferences. No negative events affecting the brand were identified.

Tarsus Pharmaceuticals has significant institutional ownership, with 252 institutional owners and shareholders holding 44,023,551 shares as of May 4, 2026. Major institutional owners include BlackRock, Inc., RTW Investments, LP, and Vanguard Group Inc. Institutional ownership collectively held 102.0% of outstanding shares as of December 2025. Individual insiders own approximately 2.93% of the company's shares, with Vivo Capital IX LLC being the largest individual shareholder.